December 17, 2021 -- Carterra has signed an exclusive Asia-Pacific and Oceania region distribution agreement with PerkinElmer. According to the agreement, PerkinElmer will market, sell, and service Carterra's flagship LSA high-throughput surface plasmon resonance platform and software used for accelerating the discovery of therapeutic antibodies.
The partnership, Carterra said, will help the company meet growing customer demand by leveraging PerkinElmer's channel infrastructure in those regions. It will also add additional tools to PerkinElmer's growing portfolio of science and biologics discovery offerings, which include its BioLegend antibody and reagent technologies.
This new agreement builds on the equity investment PerkinElmer made in Carterra in December 2020, which has resulted in collaborations between both companies involving assay development and software integration projects, Carterra said.